01—Abstract
Summary
Summary of the 8-K filed September 2, 2025. Cited figures are marked; the original filing is the authoritative source.
IQVIA Holdings Inc. (IQV) announced a planned leadership transition in its finance organization.
Michael J. Fedock, currently Senior Vice President, Financial Planning and Analysis, will succeed Ronald E. Bruehlman as Executive Vice President and Chief Financial Officer effective February 28, 2026.
The change is part of the Company's previously announced CFO succession plan. Fedock, age 50, joined the Company in 2016 and has more than 25 years of healthcare industry experience. He previously served as CFO of the Research & Development Solutions Business Unit (July 2019 to April 2021) and as CFO of IQVIA Laboratories (May 2016 to July 2019).
In connection with his promotion, his annual base salary will increase to $750,000,a with an annual cash incentive target of 100% of base salary and eligibility for annual Long Term Incentive cycles under the Company's 2017 Incentive and Stock Award Plan. Bruehlman will retire as CFO effective February 28, 2026, and transition to Senior Advisor to CEO Ari Bousbib.
The filing describes the move as ensuring continuity and a seamless transition. The announcement was made through a press release dated September 2, 2025, furnished as Exhibit 99.1.
02—Key points
Key Highlights
- Michael J. Fedock named EVP and Chief Financial Officer, effective February 28, 2026, succeeding Ronald E. Bruehlman
- Fedock's annual base salary to increase to $750,000 upon promotion, with a 100% annual cash incentive target
- Bruehlman retires as CFO effective February 28, 2026, and becomes Senior Advisor to the CEO
- Transition is part of a previously announced CFO succession plan
- Fedock has been with IQVIA since 2016, including CFO roles at R&D Solutions and IQVIA Laboratories
- Bruehlman first joined IMS Health as CFO in 2011 and returned from retirement in 2020, per the press release
03—Questions
Frequently Asked Questions
Who is the new CFO of IQVIA and when does the change take effect?
Michael J. Fedock, currently Senior Vice President of Financial Planning and Analysis, will become Executive Vice President and Chief Financial Officer effective February 28, 2026.
What happens to the current CFO, Ronald Bruehlman?
Bruehlman will retire from his CFO role effective February 28, 2026, and transition to Senior Advisor to CEO Ari Bousbib to support continuity.
What compensation changes apply to Mr. Fedock?
Effective February 28, 2026, his annual base salary will increase to $750,000, with an annual cash incentive target of 100% of base salary, subject to the Company's annual incentive program. He will also be eligible for annual Long Term Incentive cycles under the 2017 Incentive and Stock Award Plan.
What is Fedock's background?
Fedock, age 50, has more than 25 years of healthcare industry experience. He joined IQVIA in 2016, served as CFO of the R&D Solutions business unit from July 2019 to April 2021, and as CFO of IQVIA Laboratories from May 2016 to July 2019. Before joining the Company, he spent 13 years with ICON plc.
Was this CFO transition planned?
Yes. The filing states that the transition is part of the Company's previously announced Chief Financial Officer succession plan, and the press release describes it as thoughtfully planned.
04—Continue